Skip to main content
. Author manuscript; available in PMC: 2019 Jan 28.
Published in final edited form as: J Med Chem. 2018 Jun 1;61(11):5020–5033. doi: 10.1021/acs.jmedchem.8b00477

Figure 7.

Figure 7.

Efficacy of the chimeric inhibitor for gp120-protein−ligand binding determined by SPR gp120-competition analyses. (Left) Representative sensorgrams showing dose-dependent inhibition of monomeric-YU2-gp120 binding to the receptors CD4 and 17b by LJC240−L4−UM15. (Right) Dose−response curves derived from the sensorgrams of YU2-gp120-binding inhibition by LJC240−L4−UM15 and UM15 (n = 3).